Chugai Pharmaceutical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Chugai Pharmaceutical hat ein Gesamteigenkapital von ¥1,642.0B und eine Gesamtverschuldung von ¥0.0, wodurch sich der Verschuldungsgrad auf 0% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ¥1,897.8B bzw. ¥255.7B. Chugai Pharmaceutical Das EBIT des Unternehmens beträgt ¥440.8B, so dass der Zinsdeckungsgrad -133.7 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ¥764.6B.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

JP¥0

Verschuldung

Zinsdeckungsgrad	-133.7x
Bargeld	JP¥764.57b
Eigenkapital	JP¥1.64t
Gesamtverbindlichkeiten	JP¥255.72b
Gesamtvermögen	JP¥1.90t

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Chugai Pharmaceutical (TSE:4519) Is Increasing Its Dividend To ¥41.00

Jun 19

Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't

Jun 17

Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year

May 04

We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings

May 01

Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Apr 26

Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected

Mar 01

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 4519Die kurzfristigen Aktiva des Unternehmens (¥1,321.9B) übersteigen seine kurzfristigen Passiva (¥239.0B).

Langfristige Verbindlichkeiten: 4519Die kurzfristigen Vermögenswerte des Unternehmens (¥1,321.9B) übersteigen seine langfristigen Verbindlichkeiten (¥16.7B).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 4519 ist schuldenfrei.

Schulden abbauen: 4519 hatte vor 5 Jahren keine Schulden.

Schuldendeckung: 4519 hat keine Schulden und muss daher nicht durch den operativen Cashflow gedeckt werden.

Zinsdeckung: 4519 hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

Chugai Pharmaceutical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

Upcoming dividend of JP¥41.00 per share

Chugai Pharmaceutical (TSE:4519) Is Increasing Its Dividend To ¥41.00

Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't

Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year

We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings

Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Final dividend of JP¥41.00 announced

Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected

Price target increased by 7.5% to JP¥5,780

Full year 2023 earnings: EPS exceeds analyst expectations

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024

Upcoming dividend of JP¥40.00 per share at 1.5% yield

Chugai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥40.00 per share at 1.9% yield

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Financial Year 2023

Chugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥38.00 per share

Now 21% undervalued

Less than half of directors are independent

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on Feb 02, 2023

Chugai Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Apr 27, 2023

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for Full Year of Year Ending December 31, 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Chugai Pharmaceutical Co., Ltd. to Report Q2, 2022 Results on Aug 21, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for first Six Months and Full Year of Year Ending December 2022

Chugai Pharmaceutical Co., Ltd. to Report Nine Months, 2022 Results on Oct 24, 2022

Upcoming dividend of JP¥38.00 per share

Chugai Pharmaceutical Co., Ltd. to Report Q2, 2022 Results on Jul 21, 2022

Less than half of directors are independent

Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year 2022

Chugai Pharmaceutical Co., Ltd. to Report Q1, 2022 Results on Apr 25, 2022

Now 21% undervalued after recent price drop

Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 29, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Chugai Pharmaceutical Co., Ltd. Provides End of Fiscal Year Dividend Guidance for the Year Ending December 2022

Upcoming dividend of JP¥30.00 per share

Third quarter 2021 earnings released: EPS JP¥52.32 (vs JP¥36.58 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥43.02 (vs JP¥30.89 in 2Q 2020)

Chugai Pharmaceutical Co., Ltd. Obtains Regulatory Approval from the Ministry of Health, Labour and Welfare for the Anti-SARS-CoV-2 Monoclonal Antibody RONAPREVE

Chugai Pharmaceutical Co., Ltd. Announces That Roche Has Been Granted Marketing Authorization from the European Commission

Upcoming dividend of JP¥30.00 per share

Dividend reduced to JP¥30.00

CHMP Recommends EU Approval of Chugai's Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder

Chugai Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Full Year Ending December 31, 2021

Chugai Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Oct 22, 2021

Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan

Chugai Pharmaceutical Co., Ltd. Announces Management Changes

Full year 2020 earnings released: EPS JP¥131 (vs JP¥95.95 in FY 2019)

Revenue beats expectations, earnings disappoint

Chugai Pharmaceutical Co., Ltd Announces Executive Changes

New 90-day high: JP¥5,894

New 90-day high: JP¥5,406

Upcoming Dividend of JP¥25.00 Per Share

New 90-day high: JP¥5,091

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Feb 04, 2021

argenx Announces Partnership with Chugai and the Clayton Foundation

Chugai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 22, 2020

Chugai Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Jul 27, 2020

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen